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B r i e f c o m m u n i c at i o n s Evidence for the link between inflammation and cancer comes from epidemiologic and clinical studies showing that the use of nonsteroi dal antiinflammatory drugs (NSAIDs) reduces the relative risk for developing colorectal cancer (CRC) by 40-50% 1 . NSAIDs exert their antiinflammatory and antitumor effects in part by targeting prostaglandinendoperoxide synthase 2 (PTGS2). PTGS2PGE 2 signal ing has a key role in the progression of CRC 1, 2 . Previous studies showing a positive association between PTGER2 and the CpG island methyl ator phenotype (CIMP) in CRC, and an inverse correlation between NSAID use and the CIMP in CRC 3, 4 prompted us to postulate that PGE 2 may promote tumor growth by affecting the DNA methylation machinery in CRC.
We first examined the correlation between PTGS2, PGE 2 and DNA methyltransferases (DNMTs) in human CRC and found that the PGE 2 levels and PTGS2 expression are positively correlated with DNMT1 and DNMT3B expression in CRC specimens (Supplementary Fig. 1 ). We found that treatment with PGE 2 reversed the effect of a PTGS2 inhibitor, celecoxib, on the downregulation of DNMT1 and DNMT3B in cells from the human HT29 line ( Supplementary Fig. 2a ), indi cating that PGE 2 regulates DNMT expression. Indeed, PGE 2 directly upregulated DNMT1 and DNMT3B protein expression ( Fig. 1a) , but not the expression of other DNMTs (data not shown), in three human CRC cell lines.
Based on the observations that CpG island (CGI) hypermeth ylation is present in the promoters of certain tumorsuppressor and DNArepair genes in human CRC 5, 6 , we examined the human LS174T cell line and found that PGE 2 enhanced the CGI methyl ation in the promoters of CNR1 (cannabinoid receptor 1) and MGMT (O6methylguanineDNA methyltransferase) ( Fig. 1b) , as well as those of CDKN2B and MLH1 (MutL homolog 1) ( Supplementary  Fig. 2b,c) . CNR1 is silenced by CGI methylation in human CRC and acts as a tumor suppressor in vivo 7 . PGE 2 also increased CGI meth ylation in the promoters of BAX, CHEK2, NOTCH1, CAV1, NHS, MYOD1 and TMEFF2 (data not shown). PGE 2 downregulated the expression of CNR1 and MGMT ( Fig. 1c) , as well as that of CDKN2B and MLH1 ( Supplementary Fig. 2d ), at both the mRNA and pro tein levels in LS174T cells. Subsequently, we found that a PTGER4 antagonist (ONOAE208), but not a PTGER1 antagonist (SC19220) or a PTGER13 antagonist (AH6809), blocked the effect of PGE 2 on DNMT1 and DNMT3B expression ( Fig. 1d) . Moreover, knockdown of DNMT1 or DNMT3B by shRNAs attenuated the PGE 2 induced downregulation of CNR1, MGMT, CDKN2B and MLH1 in LS174T cells (Fig. 1e,f and Supplementary Fig. 2e ). Collectively, these results show that PGE 2 silences certain tumorsuppressor and DNArepair genes by enhancing their promoter CGI methylation through a PTGER4DNMT pathway in vitro.
We next confirmed our in vitro studies in vivo. Treatment of Apc Min/+ mice with PGE 2 increased Dnmt1 and Dnmt3b protein expression in colonic tumor epithelial cells ( Fig. 2a ) and accelerated intestinal adenoma growth (Fig. 2b,c) . Apc Min/+ mice harbor a germline mutation in one of the alleles of the Apc gene. Moreover, PGE 2 enhanced CGI methylation of Cnr1 and Mgmt (Fig. 2d) , as well as that of Cdkn2b and Mlh1 (Supplementary Fig. 3a ), in colonic tumor epithelial cells isolated from Apc Min/+ mice. PGE 2 also downregulated the expression of Cnr1, Mgmt, Cdkn2b and Mlh1 at both the mRNA and protein levels in colonic tumor epithelial cells from Apc Min/+ mice ( Fig. 2e and Supplementary Fig. 3b,c) . Treatment of Apc Min/+ mice with 5aza2′deoxycytidine (5AzadC) reversed the effect of PGE 2 on promoting adenoma growth ( Fig. 2f ) and inducing CGI methylation of Cdkn2b (Supplementary Fig. 4a) , showing that PGE 2 accelerates intestinal adenoma growth by regu lating CGI methylation. Notably, combined treatment with both celecoxib and 5AzadC more effectively reduced the tumor burden in Apc Min/+ mice than did treatment with either agent alone ( Fig. 2g and Supplementary Fig. 4b ). Furthermore, treatment of Apc Min/+ mice with PGE 2 reversed the effects of celecoxib on inhibiting the growth of small intestinal adenomas (Supplementary Fig. 4c) , showing that the tumorinhibitory effect of celecoxib depends on PGE 2 . Collectively, these results suggest that PGE 2 promotes intes tinal tumor growth by silencing tumorsuppressor and DNArepair genes through its effects on CGI methylation.
Our in vitro and in vivo results are of potential clinical relevance because the concentration of PGE 2 , as well as the expression level of each of PTGS2, DNMT1 and DNMT3B, were positively associated with the average of CGI methylation in the CNR1, MGMT and MLH1 promoters in human CRC specimens (Supplementary Fig. 5a) Although aberrant DNA methylation is considered to be one of the key ways by which tumor-suppressor and DNA-repair genes are silenced during tumor initiation and progression, the mechanisms underlying DNA methylation alterations in cancer remain unclear.
Here we show that prostaglandin E 2 (PGE 2 ) silences certain tumor-suppressor and DNA-repair genes through DNA methylation to promote tumor growth. These findings uncover a previously unrecognized role for PGE 2 in the promotion of tumor progression.
B r i e f c o m m u n i c at i o n s of PGE 2 concentration and the expression level of each of these genes (PTGS2, DNMT1 and DNMT3B) to the levels of CGI methylation of each individual gene (CNR1, MGMT and MLH1) were also statistically signi ficant (P < 0.05), except in the case of MLH1 ( Supplementary Table 1 ). Correlations between MLH1 and PGE2 and between MLH1 and DNMT1 did not reach statistical significance, although we observed positive trends ( Supplementary Table 1 ). In addition, the expression levels of each of CNR1, MGMT and MLH1 were negatively correlated with their respective CGI methylation levels (Supplementary Fig. 5b) .
Analysis of the human tissue samples was performed in accordance with the laboratory protocol approved by the institutional review board at The University of Texas MD Anderson Cancer Center. All experimental methods are described in the Supplementary Methods, and primers used for quantitative PCR, bisulfite PCR sequencing and methylation specific PCR are described in Supplementary Table 2 .
Dysregulation of DNMT expression is associated with human cancer progression 8, 9 . Particularly, DNMT3B expression is positively associated with CIMP in CRC 10 and colorectal adenomas 11 T  T  T  T  T   T  T  T T  T T  T T  T T  G   G   T  T  T  G  C  C G   T  T  T Control B r i e f c o m m u n i c at i o n s overexpression of DNMT1 is also associated with CIMP in CRC 12 . One study revealed similar profiles of DNMT3B methylated genes between mouse normal colonic epithelial cells and human CRC 13 . In Apc Min/+ mice, modulation of Dnmt3b expression affected colon adenoma growth 14, 15 . Consistent with these findings, our results provide the first evidence, to our knowledge, that PGE 2 promotes intestinal adenoma growth by silencing certain tumorsuppressor and DNArepair genes through induction of DNMT1 and DNMT3B. Although Dnmt3b was not responsible for CGI methylation at the Mgmt locus in Apc Min/+ mice 15 , it is possible that Dnmt1 mediates the PGE 2 enhanced CGI methylation in the Mgmt promoter in our studies. Our data further show that inhibition of CGI methylation by 5AzadC markedly sup pressed PGE 2 induced intestinal adenoma growth in Apc Min/+ mice, suggesting that demethylating agents could serve as antitumor agents in the context of PGE 2 driven cancer progression. However, these agents have been reported to activate oncogenes and promote cancer cell proliferation, migration and invasion in some in vitro studies [16] [17] [18] . In addition, global and locusspecific hypomethylation are associated with a poor prognosis of some people with CRC 19, 20 . Therefore, further investigation is needed before considering demethylating agents as a possible treatment for CRC. In addition, we discuss the association of CIMP with mutation of BRAF and KRAS, as well as with microsatellite instability in CRC, in the Supplementary Discussion section. In summary, our findings not only provide substantial insight into the intricate roles of PGE 2 in cancer progression and how DNA methylation machinery is regulated in cancer but also provide a rationale for considering the development of a new combination treatment using PTGS2 inhibitors and demethylating agents for the prevention or treatment of CRC.
